ArticleClinical ophthalmology (Auckland, N.Z.)2022
Branch Retinal Artery Occlusions, Paracentral Acute Middle Maculopathy and Acute Macular Neuroretinopathy After COVID-19 Vaccinations.
Article in Clinical ophthalmology (Auckland, N.Z.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- A Systematic Review of Ocular Complications Following Different Types of Covid-19 Vaccines.Journal of immunology research · 2025Pooled it
- The characteristics of white dot syndromes following COVID-19 Vaccines: a systematic review.International ophthalmology · 2024Pooled it
- Acute macular neuroretinopathy: is the name still appropriate?Medical hypothesis, discovery & innovation ophthalmology journal · 2026Review
- Relationship Between COVID-19 and Retinal Artery Occlusions.Journal of ophthalmology · 2026Review
- Unilateral branch retinal artery occlusion in association with COVID-19: a case report.International journal of ophthalmology · 2024Article
- [A blind spot while reading].Die Ophthalmologie · 2023Article
- A Case of Concurrent Acute Macular Neuroretinopathy and Paracentral Acute Middle Maculopathy Following Pfizer-BioNTech COVID-19 Vaccination.Turkish journal of ophthalmology · 2023Article
- Retinal vascular occlusion following SARS-CoV-2 vaccination: A VAERS database analysis.Ophthalmology science · 2023Article
- Acute Macular Neuroretinopathy and Paracentral Acute Middle Maculopathy during SARS-CoV-2 Infection and Vaccination.Vaccines · 2023Article
- Retinal Changes After COVID-19 Infection and COVID-19 Vaccination.International medical case reports journal · 2023Article
- Clinical and multimodal imaging features of acute macular neuroretinopathy lesions following recent SARS-CoV-2 infection.International journal of ophthalmology · 2023Article
- Acute macular neuroretinopathy and COVID-19 vaccination: Case report and literature review.Journal francais d'ophtalmologie · 2023Review
- Review
- Comments on: After the Storm: Ophthalmic Manifestations of COVID-19 Vaccines.Indian journal of ophthalmology · 2022Article
- Retinal artery/vein occlusion complicating SARS-CoV-2 vaccinations.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Potential retinal adverse events after COVID-19 vaccinations reported previously include paracentral acute middle maculopathy (PAMM), acute macular neuroretinopathy (AMN), and central serous chorioretinopathy. We report four cases of branch retinal artery occlusion (BRAO), one case of PAMM, and one case of AMN that occurred after administration of the Pfizer-BioNTech COVID-19 vaccine. Patients and Methods: We retrospectively reviewed the medical records of six patients who presented to Yame General Hospital or Oita University Hospital from July through October 2021. Results: Four patients (2 males) presented with visual field defects associated with BRAO, one male patient with PAMM, and one female patient with AMN after receiving the Pfizer-BioNTech COVID-19 vaccine. The mean age was 59.3 years; the mean best-corrected visual acuity was 20/21. The mean time from the last vaccination to the onset of visual field defect was 22.8 days. Five patients had received two doses of the vaccine and one patient one dose. Patients' medical history included diabetes mellitus in case 2, hypertension in cases 2, 3 and 6, and Alport syndrome and end-stage renal disease in case 6 for which the patient was undergoing regular hemodialysis. Conclusion: Although rare, retinal adverse events may occur after COVID-19 vaccinations. Further studies with a larger sample size should determine whether these retinal abnormalities are causally associated with COVID-19 vaccinations or just coincidental. Potential risks of BRAO/PAMM/AMN after COVID-19 vaccinations must be carefully weighed against the substantial benefit of COVID-19 vaccinations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.